查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1932030

超音波導引乳房切片市場（依手術類型、產品、病灶類型、影像技術和最終用途分類），全球預測，2026-2032年

Ultrasound-Guided Breast Biopsy Market by Procedure Type, Product, Lesion Type, Imaging Technology, End Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年超音波引導乳房切片市場價值為 1.8125 億美元，預計到 2026 年將成長至 1.9965 億美元，預計到 2032 年將達到 3.5834 億美元，複合年成長率為 10.22%。

關鍵市場統計數據
基準年 2025 1.8125億美元
預計年份：2026年 1.9965億美元
預測年份 2032 3.5834億美元
複合年成長率 (%) 10.22%

本文簡要概述了超音波引導乳房切片的戰略重要性，重點關注其臨床整合、工作流程影響以及相關人員的優先事項。

隨著微創診斷和精準介入治療的重要性日益凸顯，乳房醫學領域正迅速發展。超音波引導下乳房切片已成為一項基礎性技術，它使臨床醫生能夠透過即時成像識別可疑病灶，從而減少與侵入性操作相關的患者併發症，並簡化診斷流程。隨著影像精度的提高和操作效率的提升，這項技術現已成為多學科乳房診療的核心組成部分，有助於加快臨床決策，並與病理工作流程更緊密地銜接。

影像技術、設備易用性、流程工作流程和監管協調的進步如何重塑組織診斷的實踐模式和採購重點

技術融合、流程標準化和不斷變化的臨床需求正在推動該領域發生多項變革性轉變。高解析度即時成像技術已從靜態灰階顯示器發展到先進的3D和4D渲染，從而提高了病灶特徵的辨識度和針頭的可視化效果。同時，攜帶式和手持式系統也呈現出明顯的趨勢，這些系統分散了影像導引切片檢查的進行地點，使得手術可以在門診手術中心和診斷診所等傳統醫院手術室外進行。

評估近期美國關稅調整如何推動醫療設備生態系統的供應鏈重組、籌資策略轉變以及製造在地化進程。

貿易和關稅政策的變化將對醫療設備供應鏈和籌資策略產生重大影響，美國近期在2025年前的政策調整也不例外。關稅調整將影響進口系統、組件和耗材的成本基礎，從而改變依賴全整合系統和一次性手術用品的醫院和門診中心的採購趨勢。為此，採購團隊正在重新評估其籌資策略，實現供應商多元化，並提高國內製造和區域分銷中心的重要性，以降低關稅波動帶來的風險。

深度分割分析揭示了手術類型、最終使用環境、產品類型、病變分類和影像方式如何影響臨床選擇和採購決策。

了解市場區隔的細微差別對於準確指導產品開發、商業化和臨床實施工作至關重要。依手術類型分析，臨床醫生通常會根據病灶特徵和診斷目標，在粗針穿刺活體組織切片、細針穿刺切片檢查和真空輔助活體組織切片之間進行選擇；對於粗針穿刺活體組織切片，他們還會進一步選擇14G、16G和18G等不同規格的針頭，以平衡組織獲取量和侵入性。最終用戶環境決定了操作需求和採購標準：門診手術中心優先考慮便攜性、吞吐量和易於消毒；診斷中心重視影像品質和與報告系統的工作流程整合；而醫院則優先考慮企業級可維護性、互通性和全面的維護協議。

區域醫療保健系統、採購政策和基礎設施優先事項如何影響美洲、歐洲、中東和非洲以及亞太地區的採用模式和供應商策略

區域趨勢影響超音波引導乳房切片的普及模式、報銷環境、監管要求和供應鏈結構。在美洲，對門診診療模式的高度重視以及對照護現場技術的投入，影響著臨床應用，促使攜帶式成像系統和簡化的耗材（一次性耗材）更受青睞。明確的監管政策和成熟的臨床路徑支持新技術的快速應用。同時，採購趨勢傾向於在成本效益和維護支援能力之間取得平衡，確保不會中斷偵測能力。

醫療器材創新者、耗材製造商和服務供應商的競爭格局和策略行動將影響醫療保健機構的採納、檢驗和採購優先事項。

該領域的競爭動態由診斷成像技術創新者、針頭和耗材製造商以及提供培訓、維護和整合服務的服務型公司之間的相互作用所決定。成功的企業能夠將臨床級成像性能與符合人體工學的設備設計以及完善的耗材生態系統相結合，從而簡化採購和庫存管理。那些將臨床醫生對針頭可見性、組織採集效率和操作人體工學的回饋納入研發藍圖的企業，更有可能獲得更強的臨床驗證並加快產品推廣應用。

為製造商和醫療系統領導者提供可操作的策略重點，以加強產品系列、強化供應鏈、提升臨床醫生技能，並使其商業模式適應臨床環境。

產業領導者應優先考慮一系列務實且注重營運的舉措，以平衡臨床價值與商業性可行性。首先，投資涵蓋整個手術流程的產品系列——從高清晰度成像系統到可靠的針頭設計以及精簡的配件——確保客戶採購到可互操作的解決方案，而非互不相容的零散組件。在產品開發的同時，進行量化手術結果、檢體合格和安全性指標的臨床證據項目，將有助於加強與醫院董事會和門診中心管理人員的價值對話。

結合臨床醫生訪談、技術文件審查和監管分析的嚴格三角測量調查方法，可以得出檢驗的營運和策略見解，而無需猜測。

我們的研究途徑結合了定性研究和二手分析（包括對同行評審文獻、臨床實踐指南、監管文件、醫療設備註冊資訊和已發布的技術規範的分析），以建立強力的證據基礎。我們的主要研究包括對放射科醫師、病理科主任、採購負責人和醫療設備工程師進行結構化訪談，以了解實際臨床環境中的挑戰、應用促進因素和未滿足的需求。我們深入了解了臨床決策標準，包括針頭規格選擇、影像偏好和耗材生命週期管理。

整合策略要務，重點關注綜合產品解決方案、臨床醫生教育和健全的採購體系，以確保患者能夠獲得診療服務並改善診斷結果。

超音波引導下乳房切片在診斷流程中發揮至關重要的作用，它以微創精準的方式連接了影像檢測和病理診斷。該技術的未來發展將受到以下因素的影響：影像技術和穿刺針設計的進步；受貿易政策驅動的採購和供應鏈策略的務實轉變；以及製造商提供滿足不同臨床環境需求的整合解決方案的能力。隨著醫療模式的不斷分散化以及對快速、高品質診斷需求的成長，能夠整合臨床證據、產品互通性和可靠採購管道的相關人員將更有能力創造價值。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章超音波引導乳房切片市場（依手術類型分類）

  • 核心針穿刺切片
    • 14G
    • 16G
    • 18G
  • 細針穿刺切片檢查
  • 真空輔助針吸切片

第9章超音波引導乳房切片市場（依產品分類）

  • 配件
  • 針
    • 一次性的
    • 可重複使用的
  • 系統
    • 手持式
    • 桌面型

第10章 依病變類型分類的超音波導引乳房切片市場

  • 良性
  • 惡性

第11章超音波引導乳房切片市場（依影像技術分類）

  • 3D和4D
  • 即時2D

第12章 依最終用途分類的超音波引導乳房切片市場

  • 門診手術中心
  • 診斷中心
  • 醫院

第13章超音波引導乳房切片市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章超音波引導乳房切片市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國超音波引導乳房切片市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國超音波引導乳房切片市場

第17章：中國超音波引導乳房切片市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ARGON MEDICAL DEVICES, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Canon Medical Systems Corporation
  • Cardinal Health, Inc.
  • Cook Medical, Inc.
  • Danaher Corporation
  • Esaote SpA
  • Exact Sciences Corp.
  • F. Hoffmann-La Roche Ltd
  • FUJIFILM Holdings Corporation
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Izi Medical Products, LLC
  • Konica Minolta Healthcare Americas, Inc.
  • Koninklijke Philips NV
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Mindray Medical International Limited
  • Olympus Corporation
  • QIAGEN NV
  • Samsung Electronics Co., Ltd.
  • Siemens Healthineers AG
  • Sterylab SRL
  • Stryker Corporation
Product Code: MRR-7B550E008E32

The Ultrasound-Guided Breast Biopsy Market was valued at USD 181.25 million in 2025 and is projected to grow to USD 199.65 million in 2026, with a CAGR of 10.22%, reaching USD 358.34 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 181.25 million
Estimated Year [2026] USD 199.65 million
Forecast Year [2032] USD 358.34 million
CAGR (%) 10.22%

A concise orientation to the strategic importance of ultrasound-guided breast biopsy highlighting clinical integration, workflow impacts, and stakeholder priorities

The landscape of breast healthcare has progressed rapidly with increased emphasis on minimally invasive diagnostics and precision-guided interventions. Ultrasound-guided breast biopsy has become a cornerstone technique, offering clinicians the ability to localize suspicious lesions with real-time imaging, reduce patient morbidity associated with more invasive procedures, and streamline diagnostic pathways. As imaging fidelity improves and procedural ergonomics evolve, the modality is now central to multidisciplinary breast care, enabling faster clinical decision-making and tighter integration with pathology workflows.

Clinicians and health system leaders are recalibrating care pathways to leverage ultrasound-guided biopsy for both palpable and non-palpable lesions identified through screening or symptomatic presentation. From an operational perspective, the technique supports throughput in ambulatory settings and can reduce downstream diagnostic delays. Consequently, stakeholders across device manufacturing, procurement, and clinical leadership are prioritizing investments in imaging systems, needle technologies, and procedural accessories that optimize tissue yield while minimizing complications. This introduction establishes a foundation for the subsequent sections that analyze technological shifts, regulatory and trade influences, segmentation nuances, regional dynamics, competitive behaviors, and practical recommendations for leaders aiming to strengthen their position within this evolving domain.

How advances in imaging, device ergonomics, procedural workflows, and regulatory alignment are reshaping practice patterns and procurement priorities in tissue diagnostics

The field is undergoing several transformative shifts driven by technological convergence, procedural standardization, and evolving clinical expectations. High-resolution real-time imaging has advanced from static grayscale displays to more sophisticated three-dimensional and four-dimensional renderings that enhance lesion characterization and needle visualization. Concurrently, there is a clear movement toward portable and handheld systems that decentralize access to image-guided biopsy, enabling procedures in ambulatory surgical centers and diagnostic clinics outside traditional hospital suites.

Procedurally, the adoption curve has been influenced by refinements in core needle design, vacuum-assisted technology, and a renewed focus on disposable consumables that simplify sterilization protocols and reduce cross-contamination risk. These device-level changes align with broader care delivery trends that emphasize same-day diagnostics, reduced patient throughput times, and enhanced patient experience. Moreover, the intersection of imaging software enhancements-such as improved needle-tracking algorithms and integrated reporting tools-with telemedicine-enabled consults has reconfigured pre-procedural planning and post-procedural follow-up, facilitating more collaborative care between radiology, pathology, and surgical teams.

From a regulatory and reimbursement standpoint, incremental updates in clinical guidelines and coding frameworks have encouraged adoption by clarifying best practices and aligning incentives with less invasive diagnostic approaches. Meanwhile, supply chain dynamics and manufacturing innovation are driving incremental cost efficiencies, yet demand for higher-performing systems continues to create pressure for product differentiation. Taken together, these shifts are reorienting priorities for clinical champions and procurement professionals who must balance capital expenditure, consumable lifecycle costs, and the imperative to deliver high-quality, patient-centered care.

Assessing how recent United States tariff adjustments are prompting supply chain reconfiguration, procurement strategy shifts, and manufacturing localization efforts across device ecosystems

Policy changes in trade and tariff regimes can exert material influence on medical device supply chains and procurement strategies, and recent tariff developments in the United States for 2025 are no exception. Tariff adjustments affect the cost basis for imported systems, components, and consumables, thereby altering purchasing dynamics for hospitals and ambulatory centers that rely on both fully integrated systems and disposable procedural items. Procurement teams, in response, are revisiting sourcing strategies, seeking to diversify suppliers, and increasing emphasis on domestic manufacturing or regional distribution hubs to mitigate exposure to tariff volatility.

Operationally, the cumulative effects of tariffs manifest in longer lead times as supply chains pivot and as manufacturers reassess their production footprints. Contracts for service and maintenance, which frequently include imported spare parts or specialized accessories, must be renegotiated to reflect revised landed costs and potential duty mitigation strategies. In addition, research and development teams may accelerate initiatives to localize component sourcing or redesign products to reduce reliance on tariffed inputs. Regulatory compliance and documentation burdens can also intensify as vendors manage customs classifications and demonstrate traceability for clinical devices.

Clinicians and administrators alike must therefore adapt procurement frameworks to preserve clinical quality while managing financial impact. This includes embedding tariff sensitivity into contract modeling and prioritizing supplier partnerships that offer flexible manufacturing, nearshoring capabilities, or established distribution channels within tariff-favored jurisdictions. Ultimately, while tariffs do not change the clinical value proposition of ultrasound-guided biopsy, they do compel a strategic response across sourcing, contracting, and capital planning processes to sustain service delivery and maintain procedural access.

Deep segmentation insights revealing how procedure types, end-use environments, product architectures, lesion classifications, and imaging modalities determine clinical and procurement choices

A nuanced understanding of market segments is essential for targeting product development, commercialization, and clinical adoption efforts. When procedures are disaggregated by type, clinicians often choose between core needle biopsy, fine needle aspiration, and vacuum-assisted approaches according to lesion characteristics and diagnostic objectives, with core needle biopsy further refined by gauge selection such as 14G, 16G, and 18G to balance tissue yield against invasiveness. End-use settings shape operational requirements and purchase criteria: ambulatory surgical centers prioritize portability, throughput, and ease of sterilization; diagnostic centers value image quality and workflow integration with reporting systems; and hospitals prioritize enterprise serviceability, interoperability, and comprehensive maintenance contracts.

Product-level considerations influence procurement pathways and clinical preferences. Accessories must align with procedural workflows to minimize setup time and maintain sterility, needles are evaluated on performance with distinctions between disposable and reusable options that affect lifecycle cost and infection control practices, and imaging systems are categorized by form factor with handheld devices emphasizing mobility and tabletop systems emphasizing advanced imaging capabilities and integration with ancillary diagnostic tools. Lesion type drives clinical decision-making, where benign presentations often call for conservative sampling protocols and malignant-suspect lesions demand higher-yield strategies and closer coordination with pathology services. Imaging technology choices also play a critical role; the adoption of 3D and 4D modalities enhances spatial visualization and lesion mapping, while real-time 2D imaging remains a workhorse for many point-of-care biopsy procedures due to its responsiveness and established clinical workflows.

Taken together, these segmentation lenses inform the priorities of manufacturers and providers. Product development must anticipate variations in gauge and device ergonomics, commercial teams must tailor value propositions to ambulatory, diagnostic, and hospital buyers, and clinical educators must design training programs that align with the imaging technology mix and lesion-specific sampling strategies. This alignment ensures that innovations translate into improved clinical outcomes and smoother operational adoption across diverse care settings.

How regional healthcare systems, procurement policies, and infrastructure priorities in the Americas, EMEA, and Asia-Pacific shape adoption patterns and supplier strategies

Regional dynamics shape adoption patterns, reimbursement environments, regulatory expectations, and supply chain architectures for ultrasound-guided breast biopsy. In the Americas, clinical adoption is influenced by a strong emphasis on outpatient care models and investments in point-of-care diagnostics, which favor portable imaging systems and streamlined disposable consumables. Regulatory clarity and well-established clinical pathways support rapid integration of new device features, while procurement tends to balance cost-effectiveness with service and support capabilities that maintain uninterrupted procedural capacity.

Across Europe, the Middle East and Africa, heterogeneous regulatory frameworks and variable access to advanced imaging infrastructure create a mosaic of adoption rates and clinical practices. In many Western European markets, centralized pathology networks and robust hospital systems support the uptake of higher-end tabletop systems and integrated reporting solutions, whereas in parts of the Middle East and Africa, priorities often tilt toward cost-effective, ruggedized systems and consumables that are compatible with varied clinical settings. Regional procurement policies and public health investment strategies additionally influence how quickly new procedural technologies are adopted.

In the Asia-Pacific region, the combination of expanding screening programs, investments in diagnostic capacity, and a growing middle-class patient base has accelerated demand for both handheld systems that facilitate decentralized care and sophisticated tabletop platforms in tertiary centers. Local manufacturing and regional distribution networks are increasingly important in this geography, shaping how suppliers position their portfolios and service offerings. Across all regions, interoperability with digital health records, compatibility with teleconsultation frameworks, and the availability of training and technical support are critical determinants of sustained adoption and scale-up of ultrasound-guided biopsy services.

Competitive profile and strategic behaviors of device innovators, consumable manufacturers, and service providers driving adoption, validation, and procurement preference across care settings

Competitive dynamics in this space are defined by the interplay between imaging innovators, needle and consumable manufacturers, and service-oriented companies that deliver training, maintenance, and integration services. Organizations that succeed combine clinical-grade imaging performance with ergonomic device footprints and robust consumable ecosystems that simplify procurement and inventory management. Companies that align their R&D roadmaps with clinician feedback on needle visibility, tissue capture efficiency, and procedural ergonomics tend to secure stronger clinical endorsement and faster uptake.

In addition to product excellence, market leaders invest in professional education and evidence generation to demonstrate procedural safety and diagnostic concordance with core pathology outcomes. Strategic partnerships with clinical networks, diagnostic centers, and ambulatory surgical providers help scale adoption through preference formation and shared protocols. Service capabilities, including predictable maintenance schedules, responsive parts distribution, and remote diagnostic support for imaging systems, serve as differentiators for large institutional buyers concerned with uptime and total cost of ownership.

Emerging entrants often compete on niche innovations such as AI-enabled image enhancement, compact system form factors for point-of-care settings, or single-use needle designs that address infection control imperatives. These entrants can catalyze incumbents to accelerate incremental product improvements or to pursue collaborations that extend their ecosystems. Ultimately, the most resilient companies will be those that pair technological differentiation with pragmatic commercialization strategies that address the specific needs of ambulatory centers, diagnostic clinics, and hospital systems alike.

Actionable strategic priorities for manufacturers and health system leaders to enhance product portfolios, fortify supply chains, accelerate clinician competency, and align commercial models with care settings

Industry leaders should prioritize a set of pragmatic, operationally focused actions that align clinical value with commercial viability. First, invest in product portfolios that address the full procedural continuum-from high-visibility imaging systems to reliable needle designs and streamlined accessories-so that customers can procure interoperable solutions rather than disparate components. Alongside product development, clinical evidence programs that quantify procedural outcomes, sample adequacy, and safety profiles will strengthen value conversations with hospital committees and ambulatory center administrators.

Second, strengthen supply chain resilience through supplier diversification, nearshoring where feasible, and contractual mechanisms that share risk related to tariff-driven cost fluctuations. This will reduce exposure to sudden cost shifts and preserve service continuity. Third, expand training and support infrastructures to accelerate competency across care settings; targeted simulation curricula and modular training for handheld versus tabletop imaging workflows can reduce variability in sample quality and patient experience. Fourth, tailor commercial models to end-use needs, offering bundled service and consumable agreements for high-volume ambulatory centers while providing enterprise-grade maintenance and integration packages for hospitals. Finally, embrace digital enablement-integrating reporting, needle-tracking enhancements, and teleconsultation capabilities to embed these procedures into broader diagnostic pathways and to create stickier clinical relationships.

By implementing these actions, organizations can better translate technological capability into sustained clinical adoption and operational efficiency, positioning themselves to meet the nuanced demands of diversified care delivery environments.

A rigorous triangulated methodology combining clinician interviews, technical document review, and regulatory analysis to derive validated operational and strategic insights without speculative sizing

The research approach combined primary qualitative engagements with secondary analysis of peer-reviewed literature, clinical practice guidelines, regulatory documents, device registries, and publicly available technical specifications to create a robust evidence base. Primary inputs included structured interviews with practicing radiologists, pathology leads, procurement officers, and device engineers to capture real-world procedural challenges, adoption drivers, and unmet needs. These interviews provided granular insights into clinical decision criteria such as needle gauge selection, imaging preferences, and consumable lifecycle concerns.

Secondary research corroborated clinical perspectives by examining published studies on diagnostic accuracy, procedure-related complications, and imaging system performance metrics. In addition, regulatory and standards guidance was reviewed to map compliance considerations relevant to device design and labeling. The method emphasized triangulation: qualitative findings were validated against literature and technical datasheets to ensure consistency. Geographical coverage was achieved by incorporating inputs from diverse healthcare systems to reflect regional procurement behaviors and infrastructure constraints. Finally, synthesis prioritized actionable implications for stakeholders while consciously avoiding speculative market sizing, focusing instead on observable trends, operational impacts, and strategic options that decision-makers can act upon.

Synthesis of strategic imperatives emphasizing integrated product solutions, clinician education, and resilient procurement to secure procedural access and improve diagnostic outcomes

Ultrasound-guided breast biopsy occupies a pivotal role in the diagnostic pathway, bridging imaging detection and pathologic diagnosis with minimally invasive precision. The modality's future will be shaped by technological refinements in imaging and needle design, by pragmatic shifts in procurement and supply chain strategies driven in part by trade policy, and by the ability of manufacturers to deliver integrated solutions that meet the needs of diverse clinical settings. As care models continue to decentralize and the demand for rapid, high-quality diagnostics grows, stakeholders who align clinical evidence, product interoperability, and resilient sourcing will be best positioned to deliver value.

Sustained progress will depend on collaborative efforts among device developers, clinical champions, and health system leaders to translate innovation into routine practice. This includes investing in training, clarifying procedural protocols across lesion types and settings, and maintaining agile procurement strategies that can adapt to regulatory and tariff developments. By focusing on these pragmatic levers, organizations can protect procedural access and enhance patient outcomes while navigating an evolving commercial and policy landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ultrasound-Guided Breast Biopsy Market, by Procedure Type

  • 8.1. Core Needle
    • 8.1.1. 14G
    • 8.1.2. 16G
    • 8.1.3. 18G
  • 8.2. Fine Needle Aspiration
  • 8.3. Vacuum-Assisted Needle

9. Ultrasound-Guided Breast Biopsy Market, by Product

  • 9.1. Accessories
  • 9.2. Needles
    • 9.2.1. Disposable
    • 9.2.2. Reusable
  • 9.3. Systems
    • 9.3.1. Handheld
    • 9.3.2. Tabletop

10. Ultrasound-Guided Breast Biopsy Market, by Lesion Type

  • 10.1. Benign
  • 10.2. Malignant

11. Ultrasound-Guided Breast Biopsy Market, by Imaging Technology

  • 11.1. 3D And 4D
  • 11.2. Real-Time 2D

12. Ultrasound-Guided Breast Biopsy Market, by End Use

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals

13. Ultrasound-Guided Breast Biopsy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Ultrasound-Guided Breast Biopsy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ultrasound-Guided Breast Biopsy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Ultrasound-Guided Breast Biopsy Market

17. China Ultrasound-Guided Breast Biopsy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ARGON MEDICAL DEVICES, Inc.
  • 18.6. B. Braun Melsungen AG
  • 18.7. Becton, Dickinson and Company
  • 18.8. Canon Medical Systems Corporation
  • 18.9. Cardinal Health, Inc.
  • 18.10. Cook Medical, Inc.
  • 18.11. Danaher Corporation
  • 18.12. Esaote S.p.A.
  • 18.13. Exact Sciences Corp.
  • 18.14. F. Hoffmann-La Roche Ltd
  • 18.15. FUJIFILM Holdings Corporation
  • 18.16. GE HealthCare Technologies Inc.
  • 18.17. Hologic, Inc.
  • 18.18. Izi Medical Products, LLC
  • 18.19. Konica Minolta Healthcare Americas, Inc.
  • 18.20. Koninklijke Philips N.V.
  • 18.21. Medtronic plc
  • 18.22. Merit Medical Systems, Inc.
  • 18.23. Mindray Medical International Limited
  • 18.24. Olympus Corporation
  • 18.25. QIAGEN N.V.
  • 18.26. Samsung Electronics Co., Ltd.
  • 18.27. Siemens Healthineers AG
  • 18.28. Sterylab S.R.L.
  • 18.29. Stryker Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 14G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 14G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 14G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 16G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 16G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 16G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 18G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 18G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 18G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY VACUUM-ASSISTED NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY VACUUM-ASSISTED NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY VACUUM-ASSISTED NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY DISPOSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY DISPOSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY HANDHELD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY HANDHELD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY HANDHELD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY TABLETOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY TABLETOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY TABLETOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY BENIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY BENIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY BENIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY MALIGNANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY MALIGNANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY MALIGNANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 3D AND 4D, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 3D AND 4D, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 3D AND 4D, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REAL-TIME 2D, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REAL-TIME 2D, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REAL-TIME 2D, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)